[1] The Lasker Awards. Modified mRNA vaccines 2021 Lasker~DeBakey Clinical Medical Research Award[EB/OL].(2021-09-24)[2021-10-04].https://laskerfoundation.org/winners/modified-mrna-vaccines/. [2] Malone R W, Felgner P L, Verma I M. Cationic liposome-mediated RNA transfection[J]. Proc Natl Acad Sci U S A, 1989, 86(16): 6077-6081. [3] Wolff J A, Malone R W, Williams P, et al. Direct gene transfer into mouse muscle in vivo[J]. Science, 1990, 247(4949Pt1): 1465-1468. [4] Kariko K, Ni H, Capodici J, et al. mRNA is an endogenous ligand for Toll-like receptor 3[J]. J Biol Chem, 2004, 279: 12542-12550 [5] Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA[J]. Immunity, 2005, 23(2): 165-175. [6] Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J]. Nature,2017, 547(7662): 222-226. [7] Anderson E J, Rouphael N G, Widge A T, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults[J]. N Engl J Med, 2020, 383(25): 2427-2438. [8] Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells[J]. Blood, 2006, 108(13): 4009-4017. [9] Kowalski P S, Rudra A, Miao L, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery[J]. Mol Ther, 2019, 27(4): 710-728. [10]De Beuckelaer A, Grooten J, De Koker S. Type I interferons modulate CD8(+) T cell immunity to mRNA vaccines[J]. Trends Mol Med, 2017, 23(3): 216-226. [11]Linares-Fernandez S, Lacroix C, Exposito J Y, et al. Tailoring mRNA vaccine to balance innate/adaptive immune response[J]. Trends Mol Med, 2020, 26(3): 311-323. [12]Wadhwa A, Aljabbari A, Lokras A, et al. Opportunities and challenges in the delivery of mRNA-based vaccines[J]. Pharmaceutics, 2020, 12(2):102. [13]Khoury H J, Collins R H, Blum W, et al. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia[J]. Cancer, 2017, 123(16): 3061-3072. [14]Banchereau J, Palucka A K. Dendritic cells as therapeutic vaccines against cancer[J]. Nat Rev Immunol, 2005, 5(4): 296-306. [15]Alberer M, Gnad-Vogt U, Hong H S, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial[J]. Lancet, 2017, 390(10101): 1511-1520. [16]Sebastian M, Schroder A, Scheel B, et al. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer[J]. Cancer Immunol Immunother, 2019, 68(5): 799-812. [17]Geall A J, Verma A, Otten G R, et al. Nonviral delivery of self-amplifying RNA vaccines[J]. Proc Natl Acad Sci U S A, 2012, 109(36): 14604-14609. [18]Xu S, Yang K, Li R, et al. mRNA vaccine era-mechanisms, drug platform and clinical prospection[J]. Int J Mol Sci, 2020, 21(18):6582. [19]Petsch B, Schnee M, Vogel A B, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection[J]. Nat Biotechnol, 2012, 30(12): 1210-1216. [20]Feldman R A, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials[J]. Vaccine, 2019, 37(25): 3326-3334. [21]Meyer M, Huang E, Yuzhakov O, et al. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease[J]. J Infect Dis, 2018, 217(3): 451-455. [22]Roth C, Cantaert T, Colas C, et al. A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice[J]. Front Immunol, 2019, 10: 1424. [23]Pardi N, Hogan M J, Pelc R S, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination[J]. Nature, 2017, 543(7644): 248-251. [24]Schnee M, Vogel A B, Voss D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs[J]. PLoS Negl Trop Dis, 2016, 10: e0004746 [25]Van Craenenbroeck A H, Smits E L, Anguille S, et al. Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells[J]. Transplantation, 2015, 99(1): 120-127. [26]Polack F P, Thomas S J, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine[J]. N Engl J Med, 2020, 383: 2603-2615. [27]Conry R M, LoBuglio A F, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector[J]. Cancer Res, 1995, 55(7): 1397-1400. [28]Phua K K, Boczkowski D, Dannull J, et al. Whole blood cells loaded with messenger RNA as an anti-tumor vaccine[J]. Adv Health Mater, 2014, 3(6): 837-842. [29]Jindal V, Arora E, Gupta S, et al. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer[J]. Med Oncol, 2018, 35(5): 70. [30]Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors[J]. Science, 2020, 367(6476): 446-453. [31]Hobo W, Novobrantseva T I, Fredrix H, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation[J]. Cancer Immunol Immunother,2013, 62(2): 285-297. [32]Lorenzi J C, Trombone A P, Rocha C D, et al. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis[J]. BMC Biotechnol,2010, 10: 77. [33]Baeza G A, Siu E, Sun T, et al. Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection[J]. Nat Commun, 2018, 9(1): 2714. [34]Krienke C, Kolb L, Diken E, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis[J]. Science, 2021, 371(6525): 145-153. |